An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Addendum to Haematological Cancers: improving outcomes (update).
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Treosulfan (Trecondyv): CADTH Reimbursement Recommendation: Indication: Treosulfan in combination with fludarabine as part of conditioning treatment prior to allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia or myelodysplastic syndromes at increased risk for standard conditioning therapies [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Mar.
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Lutetium (177Lu) Oxodotreotide (Lutathera): CADTH Reimbursement Recommendation: Indication: For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor (SSR)–positive pancreatic neuroendocrine tumours (pNETs) in adults whose disease has progressed after treatment with a somatostatin analogue (SSA), unless there is a contraindication or intolerance [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Oct.
Blood Transfusion.
National Clinical Guideline Centre (UK).
London: National Institute for Health and Care Excellence (NICE); 2015 Nov. (NICE Guideline, No. 24.)
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Luspatercept (Reblozyl): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Dec.
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda.
Washington (DC): National Academies Press (US); 2017 Jan 12.
Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of chronic graft-versus-host disease in adults and pediatric patients aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Jul.
Belumosudil (Rezurock): CADTH Reimbursement Recommendation: Indication: For the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least 2 prior lines of systemic therapy [Internet].
Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action; Martinez RM, Osei-Anto HA, McCormick M, editors.
Washington (DC): National Academies Press (US); 2020 Sep 10.
CADTH Canadian Drug Expert Committee Recommendation: Letermovir (Prevymis — Merck Canada Inc.): Indication: Cytomegalovirus infection, prophylaxis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun.
2021 Guidelines: For the Management of Transfusion Dependent Thalassaemia (TDT) [Internet]. 4th edition.
Cappellini MD, Farmakis D, Porter J, et al., editors.
Nicosia (Cyprus): Thalassaemia International Federation; 2023.
Ruxolitinib (Jakavi): CADTH Reimbursement Recommendation: Indication: For the treatment of steroid refractory or dependent acute graft-versus-host disease in patients aged 12 years and older [Internet].
Spinal Injury: Assessment and Initial Management.
London: National Institute for Health and Care Excellence (NICE); 2016 Feb. (NICE Guideline, No. 41.)
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
WHO Guidelines for Indoor Air Quality: Selected Pollutants.
Geneva: World Health Organization; 2010.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on